Results
|
|
1.
|
|
|
|
2.
|
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. MedStar authors:
Year: 2020
Citation: - European Journal of Heart Failure. 2020 Oct 02
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Anker MS, Asteggiano R, Barac A, Bax J, Belenkov Y, Bergler-Klein J, Cardinale D, Celutkiene J, Chioncel O, Ciardiello F, Coats AJS, Cohen-Solal A, de Boer RA, Dent S, Farmakis D, Fernandez TL, Hagler-Laube ES, Henriksen PA, Hulot JS, Iakobishvili Z, Ky B, Lainscak M, Lenihan D, Lyon AR, Maack C, Moslehi J, Mueller C, Piepoli MF, Pudil R, Ruschitzka F, Seferovic P, Skouri H, Stanway S, Sterba M, Suter TM, Tocchetti CG, Von Haehling S
|
|
|
3.
|
The association between heart failure and incident cancer in women: An analysis of the Women's Health Initiative. MedStar authors:
Year: 2021
Citation: - European Journal of Heart Failure. 2021 May 01
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Anderson GL, Barac A, Cheng RK, Eaton CB, Leedy DJ, Levy WC, Qi L, Reding KW, Shadyab AH, Vasbinder AL, Wactawski-Wende J
|
|
|
4.
|
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society. MedStar authors:
Year: 2020
Citation: - European Journal of Heart Failure. 22(11):1945-1960, 2020 11.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
- Journal Article
- Research Support, N.I.H., Extramural
- Research Support, Non-U.S. Gov't
All authors: - Andres MS, Anker MS, Barac A, Bauersachs J, Belenkov Y, Bergler-Klein J, Brezden-Masley C, Cardinale D, Chioncel O, Ciardiello F, Coats AJS, Cohen-Solal A, Cornell RF, de Boer RA, de Lavallade H, Dent S, Earl H, Farmakis D, Fradley MG, Groarke JD, Hajjar LA, Herrmann J, Iakobishvili Z, Khoo V, Ky B, Lenihan D, Lopez-Fernandez T, Lyon AR, Maack C, Macedo AVS, Manisty C, Mauro MJ, Milojkovic D, Moslehi JJ, Neilan TG, Plummer C, Pudil R, Rosen SD, Ruschitzka F, Seferovic PM, Skouri H, Stanway S, Suter TM, Sverdlov AL, Tan LL, Thavendiranathan P, Thum T, Tocchetti CG, von Haehling S, Wechelaker A, Witteles RM, Wright DJ
|
|
|
5.
|
Similar clinical benefits from below-target and target dose enalapril in patients with heart failure in the SOLVD Treatment trial. MedStar authors:
- Dooley, Daniel J
- Lam, Phillip H
Year: 2018
Citation: - European Journal of Heart Failure. 20(2):359-369, 2018 02.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Aban IB, Adamopoulos C, Ahmed A, Allman RM, Anker SD, Aronow WS, Arundel C, Bhatt DL, Blackman MR, Butler J, Deedwania P, Dooley DJ, Filippatos GS, Fletcher RD, Fonarow GC, Forman DE, Kanonidis IE, Lam PH, Patel K, Pitt B, White M
|
|
|
6.
|
The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). MedStar authors:
Year: 2021
Citation: - European Journal of Heart Failure. 23(6):1052-1056, 2021 06.
Institution: - MedStar Heart & Vascular Institute
Medline publication type:
All authors: - Claggett B, Felker GM, Honarpour N, Kurtz CE, Legg JC, Liu J, Malik FI, McMurray JJV, Minamisawa M, Papolos AI, Solomon SD, Sorensen TB, Teerlink JR
|
